Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Healthcare

Grail spins back into Illumina for $8bn
Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.
Panlin picks up $148m fund
Unnamed corporates have provided capital for Panlin’s $148m fund that will focus on healthcare, digital transformation and smart hardware.
K Wah helps Hrain close series B-plus
K Wah Group’s subsidiary has taken part in the tumour therapy and drug developer’s $29.3m round, which came a year after its $28m series B round.
Chasing the light at the end of the tunnel
Global University Venturing: Covid-19 remains a threat but universities are at the forefront of fighting back
Roche fires up $448m Inflazome acquisition
Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Compass navigates IPO
Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.
Finch has the guts for $90m series D
SymBiosis and Susquehanna International Group were among a consortium of new and existing backers that supplied $90m in series D financing to Finch Therapeutics.
Kyee accumulates $64m in series D funding
Tencent has led a $64m series D round for the healthtech developer, whose shareholders already include SoftBank.

Other News

Corporate venturing deal net: 14-18 September 2020
Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.
Amwell rams its way to $742m IPO
The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.
Outset Medical pumps IPO up to $278m
The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.
Palleon packs $100m into series B
SR One, AbbVie Ventures, Takeda Ventures and Pfizer Ventures all returned having already backed the cancer and inflammatory disease drug developer at series A stage.
Olive swallows $106m
The healthcare-focused workplace management software provider hiked its total funding to about $225m as Ascension Ventures reinvested.
Corporates floor Lava with $83m
Novo Ventures and Sanofi Ventures co-led a series C round for the cancer therapy developer with backing from returning investor MRL Ventures Fund.

Editor's Picks

Amwell rams its way to $742m IPO
The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.
Grail to pour itself on to public markets
Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.
Kymera climbs to $174m IPO
The protein degradation drug developer's valuation has rocketed following an offering that achieved exits for Vertex Pharmaceuticals, Pfizer, Sanofi, Amgen and Merck & Co.
Relay receives $400m in initial public offering
The oncology therapy developer has gone public in an upsized offering that provided exits for SoftBank Vision Fund and Alphabet's GV unit.
test reg

Login